

CURRICULUM VITAE

Personal Information

- **Name:** Dr. Bassam Francis Matti
- **Current Position:** **Consultant Hematologist**
Hematology unit at Medical City Complex,
Baghdad Medical College Teaching Hospital.
Consultant Hematologist
Medical City Iraqi Bone Marrow Transplant
Centre
- **Contact Address:** Al Mansour, 605-6,25/1 Baghdad IRAQ
P O Box: 61031 Medical City Post – Baghdad - Iraq

Tel: +964 781 341 4098 Work
Mob: +964 770 205 2345

bassam_francis@yahoo.com

Educational & Professional Qualifications:

Bachelor of Medicine & Surgery MB, ChB College of Medicine University of Mosul - IRAQ	July 1997
Arab Board of Medical Specialization in Internal Medicine CABM (PhD Equivalent) Arab Board of Medical Specialization -IRAQ	April 2004
Fellowship of Iraqi Board of Medical Specialization in Internal Medicine FICMS Iraqi Board of Medical Specialization - IRAQ	May 2004
Fellowship of Iraqi Board of Medical Specialization Subspecialty in Clinical Adult Hematology FICMS Iraqi Board of Medical Specialization - IRAQ	April 2007

Licensing Practice:

Specialist Internal Medicine Ministry of Health - IRAQ	April 2004
Consultant Internal Medicine Ministry of Health - IRAQ	April 2009
Specialist Hematology Ministry of Health - IRAQ	May 2007
Consultant Hematologist Ministry of Health - IRAQ	March 2014

• **Experience records & Post held:**

- A. House officer in Internal Medicine & subspecialty , Surgery, Pediatrics, OB, Psychiatry & Emergency unit rotating between three hospitals in Mosul – Nineveh Health Directorate IRAQ**
- | | | |
|------------------------------------|------------------|---------------|
| Nuclear Medicine Hospital | 3 Months | Sep 97 |
| Ibin Sena Teaching Hospital | 12 Months | Sep 99 |
| AL-Salam Hospital | 9 Months | |
- B. Postgraduate training in Internal Medicine towards fulfillment of the training requirements of the Arab & Iraqi Board in Internal Medicine**
- Ibin Sena Teaching Hospital – the Teaching Hospital of Mosul Medical College & the Postgraduate Training Centre**
- Dec 99**
Mar 04
- C. Specialist Physician in Internal Medicine - & Adult Clinical Hematology Fellowship training**
- Hematology unit at Medical City Complex, Baghdad Medical College Teaching Hospital & the National Center of Hematology**
- I am work alongside the lead Iraqi Hematology Consultants since 2004 , Both the unit & the center are the main referral centers from all over Iraq for the management of adult hematology diseases.
- Sep 04**
Sep 07
- D. Specialist Physician Adult Clinical Hematology**
- Hematology unit at Medical City Complex, Baghdad Medical College Teaching Hospital.**
- Sep 07**
April 14
- E. Consultant Hematologist**
- Hematology unit at Medical City Complex, Baghdad Medical College Teaching Hospital.**
- Consultant Hematologist**
- Medical City Iraqi Bone Marrow Transplant Centre**
- Apr14**
Till
Date

• **Academic & Teaching Experience :**

- Actively contribute as clinical faculty in training and supervision of the undergraduate medical students in the college of Medicine – University of Baghdad
- 2004**
Till
Date
- A. Beside my daily work as a Consultant Hematologist in the Hematology Unit, I am responsible for the training and supervision of the postgraduate fellowship students in Adult Clinical Hematology and Clinical pharmacy contributing to their research work & thesis.**
- 2007**
Till
Date
- B. Supervisor for Postgraduate thesis for Master Degree & PhD candidate in Science & the clinical training for the fellow researches in hemato-pathology, microbiology and clinical pharmacy**
- 2007**
Till
Date
- C. Contribution as examiner in the mid and final examinations for undergraduate medical student in Internal Medicine & postgraduate hematology fellows & help in hematology curriculum update**
- 2004**
Till
Date

• **Professional Contribution to the specialty :**

- B.** General Secretary of the Iraqi Society of Hematology since 2009 till elected to Head
- C.** Contributing actively to the Hematology service development & quality improvement of care in Iraq being responsible for the Iraqi Hematology Guideline Writing 2013-2020
- D.** Fellow in the Clinical Adult Hematology Subspecialty Committee
- E.** Consultant Member of M.O.H Clinical Hematology Consultation Committee 2009-2012 & back in 2019
- F.** Member in Iraqi National Drug Selection Committee/ For Hematology Medications 2019

• **Summary of experience outlining Professional career :**

- A.** Sixteen years of active practice in General Internal Medicine including Emergency Care on call & various related sub specialties
- B.** Thirteen years of experience & practice in Adult Clinical Hematology including patient care, research and scientific activities
- C.** Thirteen years of teaching experience for both undergraduate & postgraduate students in the University of Baghdad - College of Medicine & College of Pharmacy - IRAQ in general internal medicine, hematology & clinical pharmacy
- D.** Participation in many refreshing & training courses during the last 10 Years in Hematology
- E.** Delivering lectures in clinical symposiums & refreshing hematology courses during the last 10 years, & inviting speaker in the national & regional Hematology conferences
- F.** Participation (Speaker or Poster Presentation) & attending many National & International Conferences listed part of it

1	American Society of Hematology Annual Meeting	US	2009
2	American Society of Hematology Annual Meeting	US	2010
3	American Society of Hematology Annual Meeting	US	2011
4	American Society of Hematology Annual Meeting	US	2012
5	American Society of Hematology Annual Meeting	Us	2013
6	15 th European Hematology Association Annual Meeting	Spain	2010
7	16 th European Hematology Association Annual Meeting	UK	2011
8	17 th European Hematology Association Annual Meeting	Netherland	2012
9	18 th European Hematology Association Annual Meeting	Sweden	2013
10	24 ^h European Hematology Association Annual Meeting	Netherland	2019
11	Iraqi Society of Hematology Annual Meeting	IRAQ	2009

12	Iraqi Society of Hematology Annual Meeting	IRAQ	2010
13	Iraqi Society of Hematology Annual Meeting	IRAQ	2011
14	Iraqi Society of Hematology Annual Meeting	IRAQ	2012
15	Iraqi Society of Hematology Annual Meeting	IRAQ	2013
16	Iraqi Society of Hematology Annual Meeting	IRAQ	2015
17	Iraqi Society of Hematology Annual Meeting	IRAQ	2016
18	Iraqi Society of Hematology Annual Meeting	IRAQ	2017
19	Iraqi Society of Hematology Annual Meeting	IRAQ	2019
20	CML GOALS Meeting	Czech Republic	2008
21	CML GOALS Meeting	Germany	2010
22	National Hematology Centre Meeting on Hemophilia Update	IRAQ	2007
23	Iraqi Summit on CML Iraqi Experience	IRAQ	2007
24	Middle East CML Forum & Conference	Jordan	2007
25	Jordanian Hematology Society Meeting	Jordan	2008
26	Thalassemia Middle East Federation Meeting	Syria	2008
27	Lebanon Hematology Society Meeting	Lebanon	2008
28	National Hemophilia Congress	Turkey	2008
29	Middle East CML Forum & Conference	Lebanon	2009
30	Thalassemia Middle East Federation Meeting	Syria	2009
31	Iraqi CLL Workshop	Turkey	2009

G. Advisory Editorial Board of

The Iraqi Journal of Hematology

<http://www.ijhonline.org/>

- H.** Participation & attending more than 50 National & International Medical Conferences during the last 16 years
- I.** Many publications in medical periodicals and abstracts in medical conferences documentation. Listed below

- **Publications**

1	Assessment of the short term outcomes of different chemotherapy protocols in adult acute lymphoblastic leukemia patients at Baghdad Teaching Hospital	Medical Science, 2020, 24(102), 435-45 https://discoveryjournals.org/medicalseience/current_issue/v24/n102/A1.pdf
2	Effect of thiopurin methyltransferase polymorphism on blood cells and plasma concentration of 6 mercaptopurine : Clinical Study	Journal of global pharma technology, April 2019,10(11):529-540 http://www.jgpt.co.in/index.php/jgpt/article/view/1839
3	Neopetrin and interferon gamma as immune response markers in beta thalassemia major patients	Asian Journal of pharmaceutical and clinical research. September 2018. Vol 11 Issue 9 https://doi.org/10.22159/ajpcr.2018.v11i9.26661
4	Prospective single center study of CML in chronic phase: switching from imatinib to a copy drug and back.	Leukemia and Lymphoma 2014 Dec;55(12):2830-4. doi: 10.3109/10428194.2014.904508. Epub 2014 Apr 22 https://pubmed.ncbi.nlm.nih.gov/24628295/
5	The price for drugs for CML is reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts	Blood,2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25. https://pubmed.ncbi.nlm.nih.gov/23620577/
6	Assessment of Soluble Fas in Patients with Chronic Myeloid Leukemia	http://www.ijhonline.org/temp/IraqiJHematol3151-1797489_002957.pdf
7	The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/ Relapsed Acute Leukemias in Adult Iraqi Patients	10.1007/s12288-013-0244-5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243413/
8	Assessment of GM-CSF level in the serum of patients with different stages of chronic myeloid leukemia before and after imatinib myesylate therapy	Iraqi J. Hematology,Nov. 2013,vol.2,Issue1 https://www.iasj.net/iasj?func=fulltext&aId=165211
9	Effectiveness of Combination Therapy with Thalidomide and Dexamethasone in Patients with Myeloma	THE IRAQI POSTGRADUATE MEDICAL JOURNAL VOL. 12, NO 1 ,2013 https://www.iasj.net/iasj?func=fulltext&aId=70993
10	Evaluation the safety of Imatinib in Iraqi Patients with CML in the chronic phase. Single centre study	Turk J Haematol. 2013 Dec; 30(4): 387–393 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874977/

11	Efficacy and Tolerance of Fludarabine and Cyclophosphamide (FC) Combination Regimen in advance stage of Chronic Lymphocytic Leukemia	J Med J 2013; Vol. 47 (4):298-307 https://journals.ju.edu.jo/JMJ/article/download/5333/5767
12	Molecular screening for T315I and F317L resistance mutations in Iraqi chronic myeloid leukemia non responders patients to Imatinib	Cancer and clinical oncology, vol.2; No. 2; 2013 http://dx.doi.org/10.5539/cco.v2n2p55
13	Follow Up of Sixty Patients with Chronic Lymphocytic Leukaemia	HE IRAQI POSTGRADUATE MEDICAL JOURNAL VOL. 12, NO 2 ,2013 https://www.iasj.net/iasj?func=fulltext&aId=76500
14	Serum Calcium And Phosphate levels in Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors	Al-Mustansiriyah Journal for Pharmaceutical Sciences, 2017, Vol. 17, No.1, June 2017 https://www.iasj.net/iasj?func=fulltext&aId=134090
15	Assessment of Interleukin 1 β Serum Level in Different Responder Groups and Stages of Chronic Myeloid Leukemia Patients on Imatinb Mesylate Therapy	Indian Journal of Hematology and Blood Transfusion volume 30, pages247–252(2014) https://link.springer.com/article/10.1007/s12288-014-0339-7
16	Case report: myeloid sarcoma:	Iraqi Journal of Hematology July 2014 Volume 3, Issue 1 66 -67 https://uomustansiriyah.edu.iq/media/attachments/95/95_2016_05_04!12_03_18_PM.pdf
16	Assessment of Interleukin 1 β Serum Level in Different Responder Groups and Stages of Chronic Myeloid Leukemia Patients on Imatinb Mesylate Therapy	Indian J Hematol Blood Transfus. 2014 Dec; 30(4): 247–252. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243414/
18	Unusual cytological features in multiple myeloma	Am. J. Hematol. 91:957, 2016 https://doi.org/10.1002/ajh.24428 https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.24428
19	Treatment outcome of 100 CML patients using nilotinib as second line therapy.	Iraqi Journal of hematology Year : 2018 Volume : 7 Issue : 2 Page : 67-71 http://www.ijhonline.org/text.asp?2018/7/2/67/239525
20	Interleukin 1 beta level and C reactive protein in primary myelofibrosis patients treated with hydroxy urea & roxulotinib.	International research journal of pharmacy. www.irjponline.com . ISSN 2230 – 8407.

21	Evaluation of Molecular Response to Imatinib in Iraqi Chronic Myeloid Leukemia Patients Using Real Time – Reverses Transcriptase-Polymerase Chain Reaction (RT-RT-PCR) – Taqman Assay	www.ccsenet.org/jmbr 10.5539/jmbr.v1n1p47 http://www.ccsenet.org/journal/index.php/jmbr/article/view/10509
22	Combination therapy of Fluadarabine and cyclophosphamide regimen in advance stage of chronic lymphocytic leukemia;	Journal of the faculty of medicine Baghdad, Vol.55; 2013
23	Spectrum of risk factor among young patients with acute coronary syndrome.	Iraqi Board Fellowship Thesis

• **Professional community service & social support**

A.	Medical Consultant ship for CARITAS Iraq, known locally as Akhuyat el Mahabba (The Brothers of love)- Nineveh Sector	2000 2004
B.	Free medical care in private clinic for low income patients referred from CARITAS	2000 2004
C.	Home medical care for disabled patients – Mosul city	2000 2004
D.	Communicating with the industry for the initiating of educational support programs for the Iraqi cancer patients (compassion program and name patients program) towards getting new novel treatment strategies and help for securing medicines for the refractory cases of different hematological disease.	2 0 0 7 till date
E.	Help in providing medical support for the refugees after their displacement from Mosul & the neighboring area when the ISIS invading the City & the province in 2014 and during the Iraqi civil war in 2006.	2006 2014
F.	Supporting the hematology cancer patients through conducting educational program and trying to support them by the medicines when not available in MOH.	2 0 0 7 till date
G.	Took the initiative towards re-establishment and activating the Iraqi Society of Hematology as a NGO to gather & support all the Iraqi hematology centers with remarkable role in the Iraqi Hematology guideline writing & actively engaged in providing update workshops to upgrade the scientific practice of these centers	2010 till date